Zhen-Wei Cai
Research Subjects
Zhen-Wei Cai has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Amrita Kamath
2 shared publicationsDonna Wei
2 shared publications- John T. Hunt
Oncology Biology, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-5400, United States
2 shared publications Joseph Fargnoli
2 shared publicationsLouis J. Lombardo
2 shared publicationsPunit Marathe
2 shared publications
Latest Publications
- 1 June 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (11) , 3224-3229
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors
- 1 June 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (11) , 3224-3229
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors
- 21 February 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (6) , 1976-1980
Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability to liberate parent drug 1 in in vitro and in vivo systems. The l-alanine prodrug 8 (also known as brivanib alaninate/BMS-582664) was selected as a development candidate and is presently in phase II clinical trials.
- 21 February 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (6) , 1976-1980
Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability to liberate parent drug 1 in in vitro and in vivo systems. The l-alanine prodrug 8 (also known as brivanib alaninate/BMS-582664) was selected as a development candidate and is presently in phase II clinical trials.